Letrozole (Infertility) — Discount Pricing

Other medications in Women's Health

• Levonorgestrel IUD
• Levonorgestrel-Ethinyl Estradiol
• Magnesium Sulfate
• Medroxyprogesterone Injection
• Methylergonovine
• Mifepristone
• Misoprostol Cervical
• Nifedipine (Tocolytic)

About Letrozole (Infertility)

Letrozole, often known by its brand name Femara, is a widely used medication to help women struggling with infertility achieve pregnancy. By stimulating ovulation, it offers a crucial step forward for many families. At TheDrugClub, we understand the financial strain of fertility treatments and are dedicated to helping our members access essential medications like letrozole at more affordable prices, easing their journey to parenthood.

What Letrozole Treats

Letrozole is an oral medication primarily used off-label for ovulation induction in women experiencing infertility. It's particularly effective for those with polycystic ovary syndrome (PCOS), a common cause of ovulatory dysfunction. For many women, letrozole has become a first-line treatment, offering a promising alternative to other fertility drugs by helping their bodies release an egg each month, thereby increasing the chances of conception.

How Letrozole Works to Boost Fertility

Letrozole belongs to a class of drugs called aromatase inhibitors. Its mechanism of action for infertility is quite clever: it temporarily blocks the enzyme aromatase, which is responsible for converting androgens into estrogen. When estrogen levels briefly drop, the brain is 'tricked' into thinking the body needs more estrogen. In response, the pituitary gland increases its production of Follicle-Stimulating Hormone (FSH). This surge in FSH then stimulates the ovaries to develop and mature follicles, ultimately leading to ovulation. Unlike some other fertility medications, letrozole is often favored for its shorter half-life and potentially lower risk of estrogenic side effects, making it a well-tolerated option for many.

Understanding Typical Costs

Letrozole is available in

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Letrozole (Infertility) is approved for (FDA label)

Letrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy.

Source: Read the full FDA label on DailyMed. Label effective date: August 20, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Letrozole (Infertility) (FDA label)

2.5 mg tablets: Yellow colored, film-coated, round shaped tablets debossed with one side 'N' and other side 'L'. 2.5 mg tablets. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 3cc750a5-cc88-4b42-b4ab-a87e760f291d. SPL document ID: f187c05f-b55e-47f9-9c42-ee3640d28bfd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Letrozole (Infertility) (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling. Bone effects [see Warnings and Precautions (5.1) ] Increases in cholesterol [see Warnings and Precautions (5.2) ] Fatigue and Dizziness [see Warnings and Precautions (5.4) ] The most common adverse reactions (greater than 20%) were hot flashes, arthralgia; flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain; and musculoskeletal. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Breckenridge Pharmaceutical, Inc., at 1-800-367-3395 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 3cc750a5-cc88-4b42-b4ab-a87e760f291d. SPL document ID: f187c05f-b55e-47f9-9c42-ee3640d28bfd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Letrozole (Infertility) (FDA label)

Pregnancy: Letrozole can cause fetal harm [see Use in Specific Populations (8.1) ] . Known hypersensitivity to the active substance, or to any of the excipients [see Adverse Reactions (6) ] . Pregnancy. ( 4 ) Known hypersensitivity to the active substance, or to any of the excipients. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 3cc750a5-cc88-4b42-b4ab-a87e760f291d. SPL document ID: f187c05f-b55e-47f9-9c42-ee3640d28bfd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Letrozole (Infertility) (FDA label)

Decreases in bone mineral density may occur. Consider bone mineral density monitoring. ( 5.1 ) Increases in total cholesterol may occur. Consider cholesterol monitoring. ( 5.2 ) Fatigue, dizziness, and somnolence may occur. Exercise caution when operating machinery. ( 5.4 ) Embryo-Fetal Toxicity: Can cause fetal harm when administered to pregnant women. Obtain a pregnancy test in females of reproductive potential. Advise females of reproductive potential to use effective contraception. ( 5.6 , 8.1 , 8.3 ) 5.1 Bone Effects Use of letrozole tablets may cause decreases in bone mineral density (BMD).

Source: FDA prescribing information (DailyMed). Set ID: 3cc750a5-cc88-4b42-b4ab-a87e760f291d. SPL document ID: f187c05f-b55e-47f9-9c42-ee3640d28bfd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Letrozole (Infertility) (FDA label)

Tamoxifen Coadministration of letrozole tablets and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels of 38% on average (Study P015). Clinical experience in the second-line breast cancer trials (AR/BC2 and AR/BC3) indicates that the therapeutic effect of letrozole tablets therapy is not impaired if letrozole tablets are administered immediately after tamoxifen. Cimetidine A pharmacokinetic interaction study with cimetidine (Study P004) showed no clinically significant effect on letrozole pharmacokinetics. Warfarin An interaction study (P017) with warfarin showed no clinically significant effect of letrozole on warfarin pharmacokinetics. Other Anticancer Agents There is no clinical experience to date on the use of letrozole tablets in combination with other anticancer agents.

Source: FDA prescribing information (DailyMed). Set ID: 3cc750a5-cc88-4b42-b4ab-a87e760f291d. SPL document ID: f187c05f-b55e-47f9-9c42-ee3640d28bfd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.